Tissue Regenix Dividends TRX

Dividends

No Dividend Data for TRX

Top Dividend Posts

Top Posts
Posted at 10/4/2024 22:19 by pj84 One of the main drawbacks of investing in early stage biotech companies is the need to keep raising funds but the report indicates the current cash should be sufficient. Read Full Thread Reply
Posted at 20/3/2024 15:32 by mickhay3 https://youtu.be/c98fRkiZB_Q?si=MOPjIJcp2geq6EEmYear-end presentation trx Dec 2023 Read Full Thread Reply
Posted at 31/10/2023 14:52 by mickhay3 Trading view trx https://ibb.co/jgDtzRV Read Full Thread Reply
Posted at 06/9/2023 14:41 by p1nkfish Do enough research and the gaps TRX can plug for STRYKER are obvious. Pocket change to them too. Read Full Thread Reply
Posted at 31/8/2023 08:41 by p1nkfish Collateralized loan note. It's a loan that pays interest and/or issues share in the company in exchange for the lender taking part. There can be a redemption date where the borrowing is paid back via issued shares, or some per year. The exact terms vary depending on the borrower and they can vary widely. The lenders can be offered a variety of ways to achieve a benefit. Sometimes the major shareholders influence how it is packaged. It is not the same as issuing discounted shares into the market. I took part in the CRX offering and TRX might make a decent candidate for raising that way especially given the share register. From memory Mills (Harwood), Sneller (Inthallo) and Griffiths were all on the CRX register and took part. Guess who is on the TRX register. Read Full Thread Reply
Posted at 03/7/2023 17:15 by cerrito I see that for no apparent reason Smith and Nephew had a big fall by FTSE100 standards today and not sure if there is an industry event that explains TRX and SN fall. Read Full Thread Reply
Posted at 25/5/2023 09:27 by cliffpeat A bit puzzled by - but interested in - the Australian Allograft (AA) deal. As I understand it, the TRX products are synthetic and replace the need for allografts. See: On the AA web site they claim: "We keep it Australian We pride ourselves on our high-quality, Australian products. We have partnered with PlusLife so there is no need to import and then distribute products from overseas." They have a page on "Synthetics" Which simply states "Coming soon" Does anyone know more about AA - it appears to be ambitious but seems to be based in a "co-working space" in Melbourne at the moment. Andrew Lambing's LinkedIn suggests he is self employed at AA since October 2019 marketing human tissue through a national team of agents. It appears that AA is already a customer of TRX - see the quote from Kirsten Lund (of TRX) here: ""This new contract for clinical trial services again represents significant repeat business from an existing customer and we believe there is potential to expand the relationship further. "These new assays also provide an important addition to our pharma services menu where our unique solution has already generated a high level of interest from new potential customers." sp just nudged up a tad this morning and like other recent announcements this seems like "ground bait" for the enticement of future commercial "fish". We shall see. DYOR Read Full Thread Reply
Posted at 13/4/2023 11:25 by pj84 It is up marginally on September from £110m to £112m Investment summary: TRX has a broad portfolio of innovative regenerative products that are in demand from surgeons. Completion of Phase 1 of its capacity expansion programme and reorganisation of the whole facility have led to operating efficiencies and comfort of supply to distribution partners. In our opinion, TRX is well-positioned to deliver persistently strong sales growth, which will drive margin expansion and highlight the low rating of the shares. An EV/sales multiple of 4x 2023E sales generates a valuation of $122m/£110m. Read Full Thread Reply
Posted at 13/4/2023 11:19 by pj84 Not sure that is correct as the valuation Hardman put on it this year is £112m and last year it was £20m less at £92m. Investment summary: TRX has a broad portfolio of innovative regenerative products that are in demand from surgeons. Completion of Phase 1 of its capacity expansion programme has comforted distribution partners and provided positive momentum. We believe TRX is well-positioned to deliver strong sales growth, which will drive margin expansion and highlight the low rating of the shares. An EV/sales multiple of 4x 2023E sales generates a valuation of $120m/£92m. Read Full Thread Reply
Posted at 23/3/2023 15:53 by timmy40 Sorry I cannot see this back at 0.50, the results were positive with +20% revenue across all divisions + cash in the bank to get to break even. The company is growing revenue in existing markets, particularly the US, as elective surgeries return/increase in frequency after Covid. They are expanding to new geographies/markets too, most probably China/Asia in the near future.The consolidation is required given the share price/no of shares in issue. A higher share price will mean the company is more marketable to institutions. It is v common in the US, which is the largest market by far for TRX and their board are Americans ? There is no dilution overall. This is all v good news. TRX's management are doing an excellent job but just imo. Read Full Thread Reply